在割敏感的前列腺癌中,BCL2驱动了割抗性,通过在致癌途径之间协调相互交叉交叉
Rahim Hirani1, Subhiksha Nandakumar2, Nabila Zaman3
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Cell reports
|May 31, 2025
概括
前列腺癌中抗雄激素剥夺疗法 (ADT) 的抵抗与BCL2上调有关. 用ADT抑制BCL2可能会延迟早期割抵抗性前列腺癌 (CRPC) 的进展.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 雌激素缺乏疗法 (ADT) 后的前列腺癌进展导致割抵抗,是癌症相关死亡的主要原因.
- 在割敏感前列腺癌 (CSPC) 中,缺乏与ADT耐药性相关的已识别的驱动因素改变.
研究的目的:
- 调查细胞信号交叉在CSPC早期ADT耐药性的作用.
- 探索向BCL2与ADT结合用于前列腺癌治疗的潜力.
主要方法:
- 从临床试验中分析RNA测序数据.
- 临床前实验研究信号通路.
主要成果:
- 在ADT后的CSPC细胞中观察到BCL2的几乎普遍上调.
- 发现BCL2可以调解雄激素受体 (AR) -BCL2和酸丁 3-激酶 (PI3K) 途径之间的相互信号传递.
- 这种交叉似乎驱动了CSPC在ADT后转化为抵抗割的前列腺癌 (CRPC).
结论:
- 在从CSPC过渡到CRPC时,BCL2起着至关重要的作用.
- 结合ADT的BCL2抑制可能是阻碍或延迟CSPC患者CRPC发育的可行策略.
- 在已经发展CRPC的患者中,BCL2抑制可能不那么有效.
相关概念视频
Interactions Between Signaling Pathways
6.6K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.6K
The Intrinsic Apoptotic Pathway
6.9K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.9K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Anaphase Promoting Complex
3.0K
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.0K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K


